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Septic shock is characterized by dysregulated vascular permeability. We hypothesized that the 
vascular permeability of endothelial cells (ECs) would be regulated by serotonin via serotonin‑Rho‑
associated kinase (ROCK) signaling. We aimed to determine the impact of 5‑hydroxyindoleacetic acid 
(5‑HIAA) on septic shock as a novel biomarker. Plasma 5‑HIAA levels and disease severity indices were 
obtained from 47 patients with sepsis. The association between 5‑HIAA levels and severity indices 
was analyzed. Permeability upon serotonin stimulation was determined using human pulmonary 
microvascular ECs. 5‑HIAA were significantly higher in septic shock patients than in patients without 
shock or healthy controls (p = 0.004). These elevated levels were correlated with severity indexes 
(SOFA score [p < 0.001], APACHE II [p < 0.001], and  PaO2:FiO2 [p = 0.02]), and longitudinally associated 
with worse clinical outcomes (mechanical ventilation duration [p = 0.009] and ICU duration [p = 0.01]). 
In the experiment, serotonin increased the permeability of ECs, which was inhibited by the ROCK 
inhibitor (p < 0.001). Serotonin increases vascular permeability of ECs via ROCK signaling. This 
suggests a novel mechanism by which serotonin disrupts endothelial barriers via ROCK signaling and 
causes the pathogenesis of septic shock with a vascular leak. Serotonin serves as a novel biomarker of 
vascular permeability.
Sepsis is a syndrome, defined as a life-threatening organ dysfunction caused by a dysregulated physiological host 
response to  infection1,2. Sepsis complicated with shock status of hypotension was previously characterized as 
“severe sepsis” or “sepsis-induced hypoperfusion” in 1991 and 2001,  respectively2. However, the existing variable 
definitions or terms (e.g., sepsis, severe sepsis, sepsis syndrome, septicemia, systemic inflammatory response 
syndrome) to recognize this syndrome have caused confusion in clinical practice. The new definition and clinical 
criteria of sepsis and septic shock was announced in 2016, as described in the “Methods”  section3. Septic shock is 
characterized by dysregulated vascular permeability of endothelial cells (ECs); however, its detailed mechanism 
remains poorly understood. The incidence rate of sepsis and septic shock is 101.8 and 19.3 per 100,000 person-
years, and the in-hospital mortality rate is 31.8% and 55.5%,  respectively4. Clinically, the treatment outcome 
of sepsis and septic shock remains poor, and most patients require admission to the intensive care unit (ICU). 
Moreover, sepsis and septic shock causes a substantial financial  burden5. This condition has an unpredictable 
clinical course, therefore, early diagnosis and treatment of sepsis (early goal-directed therapy 1-h bundle) should 
be performed, and public awareness regarding sepsis must be improved to prevent poor clinical  outcomes3,5.
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Serotonin (5-hydroxytryptamine [5-HT]) is a well-known neurotransmitter in the central nervous system 
(CNS) and is responsible for several physiological and behavioral processes such as mood, sleep, and cognitive 
 functions6. 5-HT is synthesized by two different isoforms of tryptophan hydroxylase (TPH), TPH-1 and TPH-2. 
TPH-1 is expressed in the periphery whereas TPH-2 in the  CNS7. Over 95% of 5-HT production in the whole 
body is executed in peripheral tissues, particularly in enterochromaffin cells in the intestine. Since the discovery 
of a dual system of 5-HT synthesis in the brain and periphery, a variety of pleiotropic functions of 5-HT in non-
nervous tissues have been described, including its role in  vasoconstriction8,  proliferation9, and  inflammation10. 
One of the major mechanisms that regulate vascular permeability is cellular contraction (clinically often discussed 
as vasoconstriction)11, which can be induced via the serotonin-RhoA/Rho-associated kinase (ROCK) signaling 
pathway in cell types such as vascular smooth muscle  cells12.
Moreover, 5-HT is a pivotal immunological regulator in several diseases, such as autoimmune disorders, 
inflammatory bowel  disease13, acute lung  injury14, chronic obstructive pulmonary  disease15, and pulmonary 
 hypertension12. Platelets take up serotonin from plasma via serotonin transporters, which are known to be 
enriched in serotonin storage. They release serotonin during platelet activation, and the secreted serotonin 
plays a role in platelet aggregation and  vasoconstriction16. Cloutier et al. showed that platelet-derived serotonin 
promotes endothelial vasculature leakage in an arthritis mouse  model17.
Recently, we reported that macrophage phagocytosis dysfunction was regulated by 5-HT through Rho kinase 
 activation18. For decades, Rho GTPase and ROCK, which are intracellular actin cytoskeletal organization regu-
lated by Rho GTPase, have been studied extensively in phagocyte research. Phagocytosis is regulated by the 
balance between Rho GTPases (RhoA and Rac1), such that RhoA suppresses phagocytosis and Rac1 enhances 
phagocytosis. RhoA-mediated impaired clearance of apoptotic cells by macrophages leads to a host proinflam-
matory response and a delayed tissue  repair19,20. For other cell types, there are already several reports demon-
strating its modifying effect of ROCK inhibitor for endothelial dysfunction in human disease or animal disease 
models. Kinoshita et al. applied the injection of cultured human corneal endothelial cells (CECs) treated with a 
ROCK inhibitor in a CEC disorder  patients21. Siddiqui et al. showed that ROCK1 inhibition protected against 
LPS-induced lung endothelial permeability. They confirmed its pathway in in vitro and in vivo experiments using 
p-MYPT1 and pp-MLC western  blotting22.
Because of the growing body of evidence linking 5-HT signaling with cell contraction and the RhoA/ROCK 
pathway, we examined whether the vascular permeability of ECs would be regulated by 5-HT through Rho kinase 
activation. We also examined whether the 5-HT kinetics in sepsis patients reflecting vascular leakage conditions 
would increase, and if elevated kinetics play a role as an indicator of potential clinical severity.
Our study aimed to determine the impact of 5-hydroxyindoleacetic acid (5-HIAA), a serotonin metabolite, 
as a novel biomarker of sepsis severity, and to investigate the effect of 5-HT on vascular permeability.
Results
Baseline characteristics of the patients and healthy controls. The baseline clinical characteristics 
are shown in Table 1. Among them, a strong significant difference was observed in the SOFA scores between 
sepsis patients without shock and those with shock (median: 6 [interquartile range (IQR): 3–8] vs. median: 11 
[IQR: 9–13], p < 0.001), suggesting that SOFA score would be a predominant clinical marker for evaluation of 
septic shock level.
Serotonin metabolite kinetics in sepsis patients. To investigate the associations between septic level 
and serotonin metabolite kinetics, we first analyzed the differences in plasma 5-HIAA levels between healthy 
controls and patients with sepsis. Plasma 5-HIAA levels were significantly higher in patients with sepsis than 
in healthy controls. In detail, these higher plasma 5-HIAA levels among septic patients were also identified in 
patients with septic shock (median: 14.7 ng/mL; IQR: 10.1–35.1 ng/mL), followed by sepsis patients without 
shock (median: 11.1 ng/mL; IQR: 5.8–19 ng/mL), and healthy controls (median: 4.1 ng/mL IQR: 3.4–4.5 ng/
Table1.  Characteristics of patients and healthy controls. The p values shown are the differences between the 
septic shock (−) group and shock (+) group: Mann–Whitney U-test for age, SOFA score, APACHE II score, 
and  PaO2:FiO2 ratio, and Fisher’s exact test for sex distribution and CRRT ratio. Data are expressed as median 
(interquartile range). SOFA sequential sepsis-related organ failure assessment; APACHE Acute Physiology and 
Chronic Health Evaluation; PaO2 partial pressure of arterial oxygen; FiO2 fraction of inspired oxygen; CRRT 
continuous renal replacement therapy.
Characteristics
Sepsis
ControlTotal Shock (−) Shock (+) p
Number (%) 47 (100) 14 (30) 33 (70) 7
Age (years) 76 (68–83) 73 (65–78) 77 (68–84) 0.200 34 (33.5–40)
Female (%) 18 (38) 2 (14) 16 (48) 0.040 2 (29)
SOFA score 10 (7–13) 6 (3–8) 11 (9–13)  < 0.001
APACHE-II score 14 (10–19) 11 (7–16) 16 (11–19) 0.080
PaO2:FiO2 ratio 238 (124–330) 273 (136–338) 214 (115–327) 0.600
CRRT (%) 23 (49) 4 (29) 19 (58) 0.100
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mL) (p = 0.004 by Kruskal–Wallis test, and p < 0.01 between septic shock and control, and p < 0.05 between sep-
sis without shock and control as post-hoc analysis) (Fig. 1). These results suggest a strong association between 
sepsis levels and plasma 5-HIAA levels.
Correlation between disease severity indices and serotonin metabolite kinetics. Next, we ana-
lyzed the correlation between the disease severity indices and serotonin metabolite kinetics. Plasma 5-HIAA 
levels were positively correlated with clinical disease severity indices, such as SOFA score (r = 0.6, p < 0.001) 
(Fig.  2a) and APACHE II score (r = 0.6, p < 0.001) (Fig.  2b), and negatively correlated with  PaO2:FiO2 ratio 
(r = 0.3, p = 0.02) (Fig. 2c). Sepsis patients with continuous renal replacement therapy (CRRT) had significantly 
higher plasma 5-HIAA levels than sepsis patients without CRRT (median: 20.7 ng/mL [IQR: 13.4–74.9 ng/mL] 
vs 10.1 ng/mL [IQR: 5.7–18.9 ng/dL]; p = 0.01) (Fig. 2d). These results revealed that plasma 5-HIAA levels could 
be a potential strong indicator to detect disease severity at the early stage of sepsis infection.
Longitudinal analysis: worse clinical outcome among sepsis patients with higher plasma 
5‑HIAA level. Next, we assessed the impact of plasma 5-HIAA levels on longitudinal disease progression. 
A total of 36 out of 47 sepsis patients were admitted to the ICU and attached to a mechanical ventilator. After 
dividing the 36 patients into the lower plasma 5-HIAA level group (≤ 13.6 ng/mL, n = 18) and higher level group 
(> 13.6 ng/mL, n = 18), we assessed the differences in the clinical outcomes between the two groups. Compared 
with the lower plasma 5-HIAA level group, mechanical ventilator extubation (p = 0.009) (Fig. 3a) and ICU dis-
charge (p = 0.01) (Fig. 3b) were delayed in the higher plasma 5-HIAA level group. These findings suggest that 
plasma 5-HIAA levels can be used to estimate the clinical progression of sepsis.
Effect of serotonin on ECs permeability via ROCK pathway. Finally, to investigate the effect of 5-HT 
on EC permeability, we performed in vitro experiments to analyze the permeability of 5-HT-mediated ECs using 
HPMECs. A significant difference in albumin levels was observed among the four conditions (p < 0.001) (Fig. 4). 
Compared with control, serotonin stimulation significantly increased the albumin level (median: 42.7 μg/mL 
[IQR: 30.4–53.7 μg/mL] vs 87.8 μg/mL[ IQR: 77.4–108.6 μg/mL]: p < 0.01), with less increase in serotonin levels 
despite the activation of ROCK inhibitor (median: 42.7 μg/mL [IQR: 30.4–53.7 μg/mL] vs 69.4 μg/mL [IQR: 
Figure 1.  Plasma 5-HIAA levels in patients with septic infection. Plasma 5-HIAA levels among healthy 
controls, sepsis patients without septic shock, and sepsis patients with septic shock were determined by the 
Kruskal–Wallis test and Steel–Dwass test for post-hoc analysis. *p < 0.05, **p < 0.01 by Steel–Dwass test.
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64.4–82.1 μg/mL]; p < 0.05). Our results suggest that the effect of 5-HT on EC permeability occurs through the 
ROCK activation pathway.
Discussion
This study systematically investigated the effect of plasma 5-HIAA levels on the clinical outcomes of sepsis infec-
tion. In both cross-sectional and longitudinal analyses, we identified associations between higher plasma 5-HIAA 
levels and worse clinical outcomes of sepsis. We then addressed in the in vitro experiment the potential role of 
5-HT in vascular permeability through the ROCK activation pathway, thereby suggesting a pivotal therapeutic 
target for vascular leak status in septic shock. Plasma 5-HIAA levels could be a novel biomarker of vascular 
permeability other than blood pressure and fluid resuscitation volume.
Figure 2.  Correlation between disease severity indices and plasma 5-HIAA levels. Correlation between SOFA 
score and plasma 5-HIAA level (a); between APACHE-II score and plasma 5-HIAA level (b); and between 
 PaO2:FiO2 ratio and plasma 5-HIAA level (c), by Spearman’s correlation test, and the plasma 5-HIAA level 
difference between sepsis patients without CRRT and sepsis patients with CRRT (d) by Mann–Whitney U-test.
Figure 3.  Longitudinal analysis of plasma 5-HIAA level and clinical outcome. The differences in the rate of 
mechanical ventilator extubation (a) and rate of ICU discharge (b) between the lower plasma 5-HIAA level 
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Due to the lack of evidence-based comprehensive treatment guidelines, septic shock treatment and its man-
agement are used as symptomatic treatments, which involve the use of fluid resuscitation, vasopressors, and 
antibiotics. However, septic shock remains a major health care burden in many  countries1–3. Several studies have 
used novel treatments and management for patients with septic shock for (1) modulation of the hemodynamic 
response with the use of vasopressors (norepinephrine, epinephrine, phenylephrine, and vasopressin/terlipres-
sin)2, and (2) modulation of the immunologic state with the use of CRRT 23,24, polymyxin B  hemoperfusion25, 
activated protein  C26,27, and glucocorticoid  therapy28,29. However, their impact on septic shock treatment is 
limited. Although supportive/symptomatic treatments are provided to septic shock patients, there is no specific 
or effective treatment or medication for this condition. These findings also imply the complex pathogenesis of 
sepsis and septic shock.
Regarding the pathogenesis of sepsis, Zhang et al. demonstrated the importance of 5-HT in driving sepsis 
mortality using an animal peritonitis  model30.
The reasons we decided to measure plasma 5-HIAA instead of serotonin directly are as follows: (1) 5-HIAA 
is a metabolite of serotonin and is more stable than serotonin itself, therefore would be more favorable for 
septic shock level evaluation in hospitals. (2) HPLC or ELISA: Measurement of 5-HIAA by HPLC has already 
been established for clinical diagnosis such as carcinoid tumors. In addition, costly HPLC is more reasonable 
than ELISA; in other diseases, Hynes et al. reported an association between sudden infant death syndrome and 
elevated serum serotonin or 5-HIAA levels, as measured by ELISA or HPLC. These data suggest that 5-HIAA level 
measurement by HPLC would be available for disease severity evaluation of septic shock as  well31. (3) Plasma or 
urine: Several septic shock patients enrolled in this study had complicated acute kidney failure and anuria, which 
made it difficult to collect stable urine samples for examination. Based on the above reasons, we assessed plasma 
5-HIAA levels. Several benefits of plasma 5-HIAA measurement as a novel septic shock biomarker are considered.
In this study, we identified associations between higher plasma 5-HIAA levels and worse clinical outcomes of 
sepsis. Moreover, our in vitro assays, including ROCK inhibitors, also showed the effect of 5-HT on EC perme-
ability through the ROCK activation pathway. These results were consistent with those of the abovementioned 
mouse model, and imply the importance of 5-HT pathways in septic shock pathogenesis and indicate that plasma 
5-HIAA level is a novel biomarker for the evaluation of sepsis or septic shock severity.
The RhoA/ROCK pathway has been intensively studied considering its potential therapeutic effect by target-
ing ROCK inhibition. Clinical studies with systemic administration of ROCK inhibitor were conducted among 
patients with various diseases such as  stroke32, pulmonary  hypertension33, and  angina34, which showed the ben-
eficial effect of ROCK inhibitor on disease control. In infectious diseases, viral hemorrhagic fever diseases are 
commonly characterized by an increase in vascular  permeability35,36. In terms of viral hemorrhagic fever disease, 
Eisa-Beygi et al. reported the potential feasibility of ROCK blockage as a therapeutic approach for Ebola  disease37. 
In septic shock, a sepsis-related mouse model with ROCK inhibitor was used, which also showed a protective 
effect against  sepsis38,39 or lung injury vascular  permeability22. We applied this ROCK inhibition approach to 
Figure 4.  Effect of 5-HT on endothelial cell permeability. Albumin differences among control, serotonin-added, 
serotonin and ROCK inhibitor (Y27632)-added, and ROCK inhibitor-added groups by Kruskal–Wallis test and 
Steel–Dwass test for post-hoc analysis, are shown. *p < 0.05 by Steel–Dwass test.
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our in vitro experiment, and our results also support the potential of ROCK inhibitor as a novel treatment for 
septic shock. Indeed, ROCK inhibitors and SERT inhibitors have already been clinically approved and utilized 
for the treatment of certain diseases: the former for the treatment of vasospasm and subarachnoid hemorrhage 
 complications40, and the latter for the treatment of  depression41. Clinical trials using these inhibitors to reveal 
the effect in regulation of sepsis-related vascular permeability are warranted.
This research, however, is subjected to some limitations. The first is the restricted number of patients and sam-
ples enrolled. A larger sample size would be needed to account for the high variability observed in the measure-
ments of plasma 5-HIAA levels. Obtaining informed consent from patients and families with severe symptoms, 
including septic shock, was one of the most challenging parts of this study. The second limitation concerns the 
fact that the complete mechanism of RhoA/ROCK associated vascular permeability regulation could not be 
evaluated. The following previously reported studies support our hypothesis and the data presented. Our previ-
ous study demonstrated the 5-HT signaling pathway in macrophages using RhoA inhibitor (C3 transferase) and 
ROCK inhibitor (Y-27632) and assessed the downstream signaling of ROCK by observing phospho-MYPT118. 
Guilluy et al. demonstrated the direct involvement of the 5-HT/RhoA/Rho kinase signaling pathway in pulmo-
nary artery smooth muscle cells using RhoA-GTP pulldown assay or G-LISA assay and phospho-MYPT western 
 blotting12,42. Wu et al. demonstrated that serotonin decreased transepithelial electrical resistance and reduced 
the expression of tight junction proteins. He also concluded that serotonin disrupted epithelial barrier function 
by modulating the levels of tight junction  proteins43. Although the target cells are different, the conceptual idea 
arose from these previous studies.
In addition, Rap1 is a small GTPase that regulates cell–cell adhesion. In a recent study, the pivotal role of 
the adaptor protein ras-interacting protein 1 (Rasip1) as a Rap1-effector was revealed in endothelial barrier 
 function44. It is a positive effector of endothelial integrity, which is contrary to the negative effect of RhoA/ROCK. 
To reveal the whole mechanism of our clinical observations, several types of Rho-GTPases need to be evaluated 
to explain the context of endothelial integrity. Regarding our results, further experiments to see more detailed 
involvement of 5HT-RhoA signaling by assessing activated RhoA, and visual assessment by immunofluorescence 
of the EC monolayer would be needed.
This study investigated the association between plasma 5-HIAA levels and disease outcome in sepsis infection, 
and we identified that plasma 5-HIAA levels can be a predominant biomarker of septic shock severity. We also 
found a novel role of 5-HT in vascular permeability through the ROCK activation pathway. These findings will 
contribute to the development of novel therapies and management strategies for sepsis and septic shock. Since 
there are no methods to detect ROCK activation directly as a visual marker in clinical samples (body fluids), 
we propose plasma 5-HIAA as a promising biomarker of ROCK activation in the human body as a prognostic 
marker of vascular permeability in clinical settings. This concept can be applied to other diseases (e.g., acute 
respiratory distress syndrome from any etiology, including COVID-19) in which vascular leakage is critical.
Methods
Enrollment of patients and healthy controls. This observational study was conducted at the Nagasaki 
University Hospital between August 2016 and March 2018. Adult patients (aged 18 to 90 years) admitted to the 
Nagasaki University Hospital ICU, emergency ward (EW), or infectious disease (ID) ward who were diagnosed 
with sepsis were recruited for the study. Sepsis, septic shock definitions, and clinical criteria from the third 
international consensus definitions for sepsis and septic shock were used in this  study3. Sepsis was defined as 
suspected infection and a SOFA score of more than 2 points, while septic shock was defined as requiring vaso-
pressor therapy to meet the mean arterial blood pressure (MAP) target of ≥ 65 mmHg and lactate target level 
of ≥ 2  mmol/L despite adequate fluid resuscitation. Meanwhile, pregnant patients and immunocompromised 
patients (those receiving chemotherapy, with human immunodeficiency virus infection, or treated with immu-
nosuppressive agents) were excluded. Seven healthy control volunteers and 47 patients with sepsis were recruited 
for this study. The Institutional Review Board at Nagasaki University Hospital approved the study (approval 
number: 16072514). Written consent was obtained from each participant or legally authorized surrogate. All 
researchers involved in this research read the "Declaration of Helsinki (revised in October 2013)" and "Ethical 
Guidelines for Medical Research for Humans (2014 Ministry of Education, Culture, Sports, Science and Tech-
nology / Ministry of Health, Labor and Welfare Notification No. 3).” Implement compliance.
Plasma from patients with sepsis at the time of enrollment (day 0) and healthy volunteers were collected and 
stored at − 80 °C. To assess 5-HT kinetics, the alternative plasma 5-hydroxyindoleacetic acid (5-HIAA) break-
down  product45 of 5-HT was monitored. Samples were sent to the SRL laboratory in Japan, and the plasma levels 
of 5-HIAA were measured by high-performance liquid chromatography. The baseline characteristics of patients 
and their follow-up data including SOFA score, Acute Physiology and Chronic Health Evaluation (APACHE) II 
score,  PaO2:FiO2 ratio, duration of ICU hospitalization, and ventilator treatment days were obtained.
In vitro experiment of permeability analysis. EC permeability upon 5-HT stimulation of the endothe-
lial monolayer was determined by albumin transfer using human pulmonary microvascular endothelial cells 
(HPMECs). HPMECs were obtained from Lonza (Basel, Switzerland) and cultured in EC basal medium  MV2Ⓡ 
(PromoCell, Heidelberg, Germany) supplemented with 5% heat-inactivated fetal calf serum (FCS), growth fac-
tors, and supplements provided in EC Growth Medium MV2  SupplementMixⓇ (PromoCell, Heidelberg, Ger-
many), 100 μg/mL streptomycin, and 100 U/mL penicillin in humidified 10%  CO2 at 37 °C and used for experi-
ments between the sixth and seventh passages. The ECs suspended in the culture medium were seeded on a 
6.5 mm  TranswellⓇ with a 0.4 μm pore polycarbonate membrane insert (Corning, NY, USA) at a density of 
4 × 105 cells/filter insert. The inserts were placed into a 24-well culture plate, where each well was filled with 
2 mL of culture medium and incubated at 37 °C in a humidified 5%  CO2 atmosphere. After one week of culture, 
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the cells reached confluence, and permeability measurements were performed. We measured albumin transfer 
across a cultured EC monolayer. The cells were pretreated with 10 μM Y-27632Ⓡ (Wako, Tokyo, Japan) for 30 min 
and then incubated with 1 mM serotonin (Sigma-Aldrich, MO, USA) for 30 min. Then, the treatment solution 
was aspirated, and 500 μl of PBS containing 0.1% bovine albumin was added to the upper chamber and placed 
in new wells, in which each well was filled with 700 μl of PBS only. After 15 min, the inserts were removed. The 
solution in the lower chamber was collected and the albumin concentration was measured using a Bio-Rad Pro-
tein Assay Kit (Bio-Rad, Hercules, CA, USA).
Statistical analyses. Statistical analysis was performed using SPSS 21.0 (IBM, Armonk, NY, USA). The 
Mann–Whitney U-test was used for the analysis of plasma 5-HIAA level differences between patients with and 
without CRRT. To analyze the differences in the plasma 5-HIAA levels among healthy controls, sepsis patients 
without septic shock, and sepsis patients with septic shock, and to determine the albumin levels among control, 
serotonin-added, serotonin and ROCK inhibitor (Y-27632)-added, ROCK inhibitor-added groups, the Kruskal–
Wallis tests with Steel–Dwass tests for post-hoc analysis were used. Spearman’s correlation test was used to 
analyze the correlations between disease severity indices (SOFA score, APACHE II score, or  PaO2:FiO2 ratio) 
and plasma 5-HIAA levels. In a longitudinal analysis, a log-rank test was performed to analyze the association 
between plasma 5-HIAA level (median value) and duration of ICU hospitalization or ventilator treatment.
Data availability
All data are fully available without restriction.
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